Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Fountain secures $6m to fund anti-aging research

By Tom Salemi | May 19, 2020

Fountain Therapeutics, a biopharmaceutical company building a pipeline of therapeutics to treat age-related diseases by reversing cellular age, closed on an additional $6 million in a Series A, bringing its total to $11 million. Khosla Ventures led the round that drew capital from Nan Fung Life Sciences, the provider of initial $5 million in 2018.

In a press release, the company said it will use the capital to build out the senior leadership team and “enhance” the capabilities of the company’s technology platform. Fountain also plans to advance novel therapeutics identified by the platform through preclinical testing in animals.

“Over the last two years we have built and validated our platform technology, which includes an AI-based drug screening platform and animal models for disease modeling and preclinical testing,” CEO John Dimos, PhD, stated in the release. “This has allowed us to generate unprecedented insights into the cellular aging process. Today, thanks to the help of our investors, we are in a strong financial position to rapidly discover and develop a pipeline of novel therapeutics to target and reverse the biological process of aging with the potential to improve the quality of life for our aging population.”

Co-founder Thomas Rando, MD., PhD., who chairs the company’s board, said he has spent 20 years in aging research. He said he co-founded the company to target the underlying mechanisms of aging to treat disease.

“Fountain’s technology allows us to solve the challenges of aging with an unbiased and phenotypic-driven approach,” he stated in the release.”This, together with the outstanding team of experts in aging research, places the company in a unique position to reveal new possibilities and radically transform the landscape of drug discovery and development for the treatment of age-related health conditions.”


Filed Under: Drug Delivery, Drug Discovery, Drug Discovery and Development
Tagged With: anti-aging, venture capital
 

Related Articles Read More >

A display of DNA sequencing output from an automated ABI 373 sequencer. [National Human Genome Research Institute (NHGRI)]
Helix and Recursion join forces in quest to crack the AI-driven drug discovery code
Ypsomed Ypsodose patch injector
ten23 health to develop large-volume injectables for Ypsomed’s YpsoDose
Shasqi
Click chemistry breakthroughs drive Shasqi and J&J cancer alliance
Shasqi
Nobel-connected startup Shasqi deepens J&J partnership on CAPAC platform
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE